Cumberland Pharmaceuticals Inc (CPIX)

Nov 10, 2026

Cumberland Pharmaceuticals (NASDAQ: CPIX) reported strong Q3 2026 financial results, highlighted by a $100 million cash infusion from a strategic transaction with Apotex Health. This significantly strengthened the company's balance sheet, leading to a special dividend of $1.50 per share and a new share repurchase program. The company is now focusing on advancing its late-stage clinical pipeline, particularly the ifetroban program for Duchenne Muscular Dystrophy, with an NDA submission planned following positive FDA meetings.

Nov 10, 2026

Cumberland Pharmaceuticals (CPIX) announced a net income of $77.8 million for Q3 2026, driven by a gain from the disposal of discontinued operations in a strategic transaction with Apotex Health. The company reported total revenue of $2.2 million and revealed plans to submit a New Drug Application to the FDA for ifetroban for cardiomyopathy associated with Duchenne muscular dystrophy, along with positive Phase 2a systemic sclerosis study results. Institutional investors showed mixed activity, with some adding and others decreasing their positions in CPIX stock.

Nov 3, 2026

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced plans to submit a New Drug Application (NDA) to the FDA for Traditional Approval of ifetroban for cardiomyopathy associated with Duchenne muscular dystrophy (DMD). This decision follows a pre-NDA meeting with the FDA and recent board approval, leveraging data from the Phase 2 FIGHT DMD trial and natural history databases. Although the FDA granted rolling review, it questioned if the proposed data package meets substantial evidence standards, potentially requiring additional analyses or even a Phase 3 trial.